Tag Archives: Paul Cole

Sustained release fluvastatin formulations – The UK Court of Appeal opinion in Activis UK Limited v Novartis AG [2010] EWCA Civ 82

Post from Paul Cole Sometimes a decision as to obviousness hinges on a single short point. In Graham v John Deere, the tipping point testimony was during cross-examination of the witness for the patentee, when he said that the allegedly … Continue reading

Posted in Non-U.S. Practice | Tagged , , , | Leave a comment

Views of the EPO Enlarged Appeal Board in Treatment by surgery/MEDI-PHYSICS G 0001/07

Under what circumstances is injection a prohibited surgical method? Views of the EPO Enlarged Appeal Board in Treatment by surgery/MEDI-PHYSICS G 0001/07 .  Opinion From Paul Cole The present proceedings resulted from a referral in decision T 0992/03 relating to EP-A-1066537. … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , | Leave a comment

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

From Paul Cole The Lilly patent for olanzapine has been litigated in many jurisdictions including the US, Canada, the Czech Republic, Finland, Levitra order online Romania, Slovakia, Slovenia, Spain, China and Hungary. In US Court of Appeals for the Federal … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , | Leave a comment

Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result

From Paul Cole of Lucas & Cole On February 9th the Court of Appeal ([2010] EWCA Civ 33; Jacob L.J.) held that Human Genome Sciences Patent EP-B-093 cheap cialis online 9804 for Neutrokine-α did not meet the industrial applicability requirement … Continue reading

Posted in Utility/How-To-Use | Tagged , , , , | Leave a comment